S9 Ep40: Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis
Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care beyond daratumumab, and the importance of confirming earlier post-hoc results from the placebo-controlled phase 3 VITAL trial in the ongoing AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.